A Phase 0/2 study of LY3214996 (ERK inhibitor) in combination with abemaciclib (CDK4/6 inhibitor) in recurrent glioblastoma participants scheduled for resection to evaluate CNS penetration.

**Dosing regimen – Phase 0**
Abemaciclib = 150mg PO BID x 6 days
LY3214996 = 200mg PO QD x 6 days

**Dosing regimen – Phase 2 (21-day cycles)**
Abemaciclib = 150mg PO BID x 21 days
LY3214996 = 200mg PO QD x 21 days

**Inclusion Criteria**
- Progression following Stupp regimen
- Sufficient archival tissue for eligibility testing:
  - Tissue must demonstrate:
    - RB+ on IHC or no RB mutations on NGS
    - Chromosomal loss of CDKN2A/B/C or CDK4/6 amp. on array CGH or NGS
    - pERK+ on IHC

**Exclusion Criteria**
- Retinal diseases such as central or branch retinal artery or venous occlusion
- Prior CDK4/6 or ERK1/2 therapy
- Screening mean QT interval ≥470ms
- History of syncope/arrhythmia

**STUDY TIMELINE**
- Tissue Eligibility: 7-14 days
- Trial Screening: Up to 28 days
- Phase 0: 6 days
- Phase 2 Tissue Eligibility: 1-2 weeks
- Phase 2: 21-day cycles

**PARTNER WITH US**
When you refer a patient to the Ivy Center, we will partner with you and your team on a path forward.
To determine your patient’s trial eligibility, please call 602.406.8605 or visit IvyBrainTumorCenter.org.